Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 1, 1999, Pages 79-86

  Lister, Philip D ^a   Sanders, Christine C ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; LEVOFLOXACIN;

ARTICLE; BACTERIAL COUNT; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PNEUMONIA; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TIME;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; OFLOXACIN; PENICILLIN RESISTANCE; STREPTOCOCCUS PNEUMONIAE;

EID: 0032957758     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.1.79     Document Type: Article

References (31)

1. Scully, B. E. (1989). Therapy of respiratory tract infections with quinolone antimicrobial agents. In Quinolone Antimicrobial Agents (Wolfson, J. S. & Hooper, D. C., Eds), pp. 143-65. American Society for Microbiology, Washington, DC.
2. Barry, A. L., Fuchs, P. C., Allen, S. D., Brown, S. D., Jorgensen, J. H. & Tenover, F. C. (1996). In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of of loxacin: interpretive criteria and quality control limits. Journal of Antimicrobial Chemotherapy 37, 365-9.
3. Fu, K. P., Lafredo, S. C., Foleno, B., Isaacson, D. M., Barrett, J. F., Tobia, A. J. et al. (1992). In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 36, 860-6.
4. Spangler, S. K., Jacobs, M. R., Pankuch, G. A. & Appelbaum, P. C. (1993). Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829. Journal of Antimicrobial Chemotherapy 31, 273-80.
5. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy 35, 230-2.
6. Forrest, A., Nix, D. E., Ballow, C. H., GOSS, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
7. Hyatt, J. M., McKinnon, P. S., Zimmer, G. S. & Schentag, J. J. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome - focus on antimicrobial agents. Clinical Pharmacokinetics 28, 143-60.
8. Sanders, W. E. (1992). Oral ofloxacin: a critical review of the new drug application. Clinical Infectious Diseases 14, 539-54.
9. Plouffe, J. F., Herbert, M. T., File, T. M., Baird, J., Parsons, J. N., Kahn, J. B. et al. (1996). Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrobial Agents and Chemotherapy 40, 1175-9.
10. Khan, F. A. (1990). Ciprofloxacin for respiratory tract infections. In Fluoroquinolones in the Treatment of Infectious Diseases (Sanders, W. E. & Sanders, C. C., Eds), pp. 87-98. Physicians' and Scientists' Publishing Co., Glenview, IL.
11. Cooper, B. & Lawlor, M. (1989). Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia (brief clinical observation). American Journal of Medicine 87, 475.
12. Gordon, J. J. & Kauffman, C. A. (1990). Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. American Journal of Medicine 89, 383-4.
13. Child, J., Mortiboy, D., Andrews, J. M., Chow, A. T. & Wise, R. (1995). Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrobial Agents and Chemotherapy 39, 2749-51.
14. Israel, D., Gillum, J. G., Turik, M., Harvey, K., Ford, J., Dalton, H. et al. (1993). Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin follwoing multiple oral doses in healthy volunteers. Antimicrobial Agents and Chemotherapy 37, 2193-9.
15. Lister, P. D., Pong, A., Chartrand, S. A. & Sanders, C. C. (1997). Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrobial Agents and Chemotherapy 41, 1926-32.
16. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA.
17. Blaser, J., Stone, B. B. & Zinner, S. H. (1985). Two-compartment kinetic model with multiple artificial capillary units. Journal of Antimicrobial Chemotherapy 15, Suppl. A, 131-7.
18. Chien, S.-C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J. et al. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy 41, 2256-60.
19. Anon. (1997). Physicians' Desk Reference, 51st edn. Medical Economics Data, Montvale, NJ.
20. Schentag, J. J., Nix, D. E. & Adelman, M. H. (1991). Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP, The Annals of Pharmacotherapy 25, 1050-7.
21. Smith, J. T. (1990). Effects of physiological cation concentration on 4-quinolone absorption and potency. In The 4-Quinolones: Antibacterial Agents In Vitro (Crumplin, G.C., Ed.), pp. 15-21. Springer-Verlag, London.
22. Visalli, M. A., Jacobs, M. R. & Applebaum, P. C. (1997). Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagnostic Microbiology and Infectious Disease 28, 131-7.
23. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1996). MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrobial Agents and Chemotherapy 40, 362-6.
24. Spangler, S. K., Jacobs, M. R. & Applebaum, P. C. (1997). MIC and time-kill studies of antipneumococcal activity of GV 118819X (Sanfetrinem) compared with those of other agents. Antimicrobial Agents and Chemotherapy 41, 148-55.
25. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965-72.
26. Daikos, G. L., Jackson, G. G., Lolans, V. T. & Livermore, D. M. (1990). Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. Journal of Infectious Diseases 162, 414-20.
27. Daikos, G. L., Lolans, V. T. & Jackson, G. G. (1991). First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrobial Agents and Chemotherapy 35, 117-23.
28. Dudley, M. N. (1991). Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. American Journal of Medicine 91, Suppl. 6A, 45S-50S.
29. Smith, J. T. (1984). Awakening the slumbering potential of the 4-quinolone antibacterials. Pharmaceutical Journal 233, 299-305.
30. Cars, O. & Odenholt-Tornqvist, I. (1993). The post-antibiotic sub-MIC effect in vitro and in vivo. Journal of Antimicrobial Chemotherapy 31, Suppl. D, 159-66.
31. Licata, L., Smith, C. E., Goldschmidt, R. M., Barrett, J. F. & Frosco, M. (1997). Comparisons of the post-antibiotic and post-antibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, 950-5.